Thomas Sepe, MD
Gastroenterology · Providence, RINPI 1508937889
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $253,790 of the $307,071 with a category attached, or 82.6%. 37 manufacturers reported payments, led by Gilead at 58.8% of the total. 2025 is the largest year on record at $115,069, 2.5 times the $46,531 reported in 2019. Among gastroenterology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 948 payments — averaging $323.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$181K
- Madrigal Pharmaceuticals$60K
- Ipsen Biopharmaceuticals, Inc$30K
- AbbVie$11K
- Intercept Pharmaceuticals, Inc.$9K
- Cook Incorporated$3K
- plus $13K from 31 others
Across 139 payments — averaging $3490.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$274K
- Intercept Pharmaceuticals, Inc.$111K
- Novartis$54K
- AbbVie$21K
- Bristol Myers Squibb$10K
- Intercept Pharma Europe Ltd.$8K
- plus $6K from 1 others
What the payments were for
- Consulting fees$12,7634%
- Speaking & faculty fees$253,79083%
- Travel & lodging$14,0145%
- Food & beverage$26,5049%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$58,207
- Epclusa$57,982
- Livdelzi$39,100
- IQIRVO$30,247
- Vemlidy$30,045
- OCALIVA$7,699
- Mavyret$6,997
- Olympus Tissue Acquisition Devices$2,475
- Olympus Hemostasis Devices$2,475
- FibroScan$1,000
- CC-90001$761
- ZEPOSIA$234
- GI Genius$173
- RESMETIROM$167
- Skyrizi$126
- GENERAL - BILIARY DEVICES$125
- VOQUEZNA$125
- Ozanimod$120
- XIFAXAN$118
- CUVRIOR$107
How this compares
$307,071 in reported general payments places this provider in the 95th percentile of 85 gastroenterology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 15 | $223,739 |
| XifaxanRifaximin | 19 | $55,567 |
| VemlidyTenofovir Alafenamide | 21 | $28,820 |
| Ursodiol | 109 | $24,090 |
| LinzessLinaclotide | 29 | $20,009 |
| Famotidine | 1,040 | $18,676 |
| CreonLipase/Protease/Amylase | 13 | $16,962 |
| Omeprazole | 1,031 | $14,630 |
| Mesalamine | 32 | $13,426 |
| Dexlansoprazole DrDexlansoprazole | 23 | $6,058 |
| TrulancePlecanatide | 11 | $5,684 |
| Tenofovir Disoproxil Fumarate | 27 | $4,737 |
| Pantoprazole Sodium | 467 | $3,923 |
| Colchicine | 12 | $1,920 |
| Esomeprazole Magnesium | 45 | $1,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $8,628 | $223,73915 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,102 | $61,25230 claims |
| AbbVieLinzess, Creon | $10,994 | $36,97142 claims |
| GileadVemlidy | $180,519 | $28,82021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 85 gastroenterology providers in Rhode Island.
Other gastroenterology in Providence
- Paul AkermanProvidence$123K
- Sean FineProvidence$55K
- Breton RousselProvidence$50K
- Alan EpsteinProvidence$36K
- Samir ShahProvidence$28K
- Lisa MuellerProvidence$25K
- Nabil ToubiaProvidence$20K
- Thaer AbdelfattahProvidence$17K
- Eric NewtonProvidence$16K
- William ChenProvidence$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.